In the wake of ingenious endeavors by the Trump Administration and the US DoGE, we encounter a shocking and concerning reality: Medicare and Medicaid are regularly skipping out on billions of dollars spent on modern weight-loss medications, AOMs. These expensive medications offer the healthiest relief from weight gain, yet their lack of coverage here is a significant oversight that we must confront as a nation.
elp with the Administration on this issue could lead to immense savings for patients and taxpayers. Over the next decade, if Medicare or Medicaid doesn’t cover AOMs, medical costs in the U.S. could rise by up to $9.1 trillion, resulting in an economic blow of $14 trillion and a substantial tax punch of $2.5 trillion. This underscores the urgent need for expanded coverage of AOMs to prevent such savings.
The U.S. Obesity Epidemic, while severe, is not alone in宁波. In 2024, a 2024 committee report estimated that obesity-related medical expenses could hit the economy by as much as $14 trillion over a decade, while the share to taxpayers could rise to nearly two-thirds of federal revenues, affecting national security and military capabilities. –
Moreover, theinine on the potential of AOMs to save trillions of dollars in healthcare costs is staggering. In 2019,Heart Disease cost over $250 billion annually, with a study showing AOM use in patients with heart disease reduced health care costs by $7,502 annually. This cost saving oversight, overlooked in previous decades, would have massive economic benefits if covered under coverage.
Under the CMS’s proposal to expand AOM coverage, a bipartisan effort supported by Dr. Mehmet Oz, expanding Medicare and Medicaid to include AOMs is the Hong Kong solution. If implemented, this would not only cut healthcare costs but also mitigate future wasteful spending. If the administration supports this, not only would it solidify America’s health败, but it would also help achieve economic greatness by addressing the root causes of obesity.
